PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer

by Shankar, Bairavi, Naidoo, Jarushka
Published in J Thorac Dis (2018)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities

by Naidoo, Jarushka, Suresh, Karthik
Published in Oncologist (2020)

Immune-Related Adverse Events: A Case-Based Approach

by Connolly, Caoilfhionn, Bambhania, Kalindi, Naidoo, Jarushka
Published in Front Oncol (2019)

An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition

by Naidoo, Jarushka, Dykema, Arbor, D’Alessio, Franco
Published in J Clin Invest (2018)

Successful Treatment of Scar Pain with Scrambler Therapy

by Yarchoan, Mark, Naidoo, Jarushka, Smith, Thomas J
Published in Cureus (2019)

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer

by Wills, Beatriz, Brahmer, Julie R., Naidoo, Jarushka
Published in Curr Treat Options Oncol (2018)

What does the future hold for immunotherapy in cancer?

by Naidoo, Jarushka, Li, Bob T., Schindler, Katja, Page, David B.
Published in Ann Transl Med (2016)

The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?

by Page, David B, Naidoo, Jarushka, McArthur, Heather L
Published in NPJ Breast Cancer (2015)

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities

by Suresh, Karthik, Naidoo, Jarushka, Lin, Cheng Ting, Danoff, Sonye
Published in Chest (2018)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma

by Rosner, Samuel, Agrawal, Yuri, Sun, Daniel Q, Aygun, Nafi, Schollenberger, Megan D, Lipson, Evan, Naidoo, Jarushka
Published in J Immunother Cancer (2020)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

by Page, David B, Naidoo, Jarushka, Momtaz, Parisa, Bogatch, Kita, Kuk, Deborah, Panageas, Katherine, Yuan, Jianda, Wolchok, Jedd D, Postow, Michael
Published in J Immunother Cancer (2014)

2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors

by Naidoo, Jarushka, Hu, Chen, Schrek, Karisa, Connolly, Roisin, Santa-Maria, Cesar, Lipson, Evan, Mehra, Ranee, Bettegowda, Redmond, Kristin, Venkatesan, Arun, Grossman, Stuart
Published in J Clin Transl Sci (2018)

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

by Cappelli, Laura C., Brahmer, Julie R., Forde, Patrick M., Le, Dung T., Lipson, Evan J., Naidoo, Jarushka, Zheng, Lei, Bingham, Clifton O., Shah, Ami A.
Published in Semin Arthritis Rheum (2018)

Adaptive neoadjuvant chemotherapy guided by (18)F-FDG-PET in resectable non-small-cell lung cancers: the NEOSCAN trial

by Chaft, Jamie E., Dunphy, Mark, Naidoo, Jarushka, Travis, William D., Hellmann, Matthew, Woo, Kaitlin, Downey, Robert, Rusch, Valerie, Ginsberg, Michelle S., Azzoli, Christopher G., Kris, Mark G.
Published in J Thorac Oncol (2015)

Cardiovascular toxicities associated with immune checkpoint inhibitors

by Hu, Jiun-Ruey, Florido, Roberta, Lipson, Evan J, Naidoo, Jarushka, Ardehali, Reza, Tocchetti, Carlo G, Lyon, Alexander R, Padera, Robert F, Johnson, Douglas B, Moslehi, Javid
Published in Cardiovasc Res (2019)

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management

by Naidoo, Jarushka, Reuss, Joshua E, Suresh, Karthik, Feller-Kopman, David, Forde, Patrick M, Mehta Steinke, Seema, Rock, Clare, Johnson, Douglas B, Nishino, Mizuki, Brahmer, Julie R
Published in J Immunother Cancer (2020)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series

by Moseley, Kendall F., Naidoo, Jarushka, Bingham, Clifton O., Carducci, Michael A., Forde, Patrick M., Gibney, Geoffrey T., Lipson, Evan J., Shah, Ami A., Sharfman, William H., Cappelli, Laura C.
Published in J Immunother Cancer (2018)

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

by Braaten, Tawnie J, Brahmer, Julie R, Forde, Patrick M, Le, Dung, Lipson, Evan J, Naidoo, Jarushka, Schollenberger, Megan, Zheng, Lei, Bingham, Clifton O, Shah, Ami A, Cappelli, Laura C
Published in Ann Rheum Dis (2019)

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials

by Li, Bob T., Barnes, Tristan A., Chan, David L., Naidoo, Jarushka, Lee, Adrian, Khasraw, Mustafa, Marx, Gavin M., Kris, Mark G., Clarke, Stephen J., Drilon, Alexander, Rudin, Charles M., Pavlakis, Nick
Published in Lung Cancer (2016)

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

by Arbour, Kathryn C., Naidoo, Jarushka, Steele, Keith E., Ni, Ai, Moreira, Andre L., Rekhtman, Natasha, Robbins, Paul B., Karakunnel, Joyson, Rimner, Andreas, Huang, James, Riely, Gregory J., Hellmann, Matthew D.
Published in PLoS One (2017)